PTC Inc. (PTC) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.88%. A quarter ago, it was expected that this product development software maker would post earnings of $1.43 per share when it actually produced earnings of $1.54, delivering a surprise of 7.69%.Over the last four quar ...

[PTC First Fiscal Quarter 2025 Results](index=1&type=section&id=PTC%20First%20Fiscal%20Quarter%202025%20Results) This section outlines PTC's Q1 FY2025 financial performance and strategic initiatives [Q1 FY2025 Performance Highlights](index=1&type=section&id=Q1%20FY2025%20Performance%20Highlights) PTC reported solid Q1 FY2025 results, meeting guidance with 11% constant currency ARR growth and over 25% cash flow growth, alongside strategic realignment and share repurchases Q1 FY2025 Key Financial Metrics | Metric | Q1'25 | Q1'24 | YoY Change | Q1'25 Guidance | | :--- | :--- | :--- | :--- | :--- | | **Constant Currency ARR** | $2,277M | $2,059M | 11% | ~10.5% growth | | **Operating Cash Flow** | $238M | $187M | 27% | ~$234M | | **Free Cash Flow** | $236M | $183M | 29% | ~$230M | | **Revenue** | $565M | $550M | 3% | $540M to $570M | | **GAAP EPS** | $0.68 | $0.55 | 23% | $0.28 to $0.52 | | **Non-GAAP EPS** | $1.10 | $1.11 | (0%) | $0.75 to $0.95 | - Management highlighted solid performance with **11% constant currency ARR growth** and **over 25% cash flow growth**, which was in line with guidance[3](index=3&type=chunk) - The company initiated a go-to-market organization realignment to better serve vertical industries and drive consistent growth[4](index=4&type=chunk) - PTC resumed its share repurchase program, repurchasing **$75 million** of its stock in Q1 FY2025[8](index=8&type=chunk) [Fiscal Year 2025 and Second Quarter Guidance](index=2&type=section&id=Fiscal%20Year%202025%20and%20Second%20Quarter%20Guidance) PTC reaffirmed FY2025 constant currency ARR and free cash flow guidance, lowered EPS, and provided Q2 FY2025 projections including continued share repurchases FY2025 and Q2'25 Guidance | Metric | FY'25 Guidance | FY'25 YoY Growth | Q2'25 Guidance | | :--- | :--- | :--- | :--- | | **Constant Currency ARR Growth** | 9% to 10% | 9% to 10% | ~9.5% | | **Operating Cash Flow** | $850M to $865M | 13% to 15% | ~$274M | | **Free Cash Flow** | $835M to $850M | 14% to 16% | ~$270M | | **Revenue** | $2,430M to $2,530M | 6% to 10% | $590M to $620M | | **GAAP EPS** | $3.36 to $4.24 | 8% to 36% | $0.79 to $1.05 | | **Non-GAAP EPS** | $5.30 to $6.00 | 4% to 18% | $1.30 to $1.50 | - FY2025 cash flow guidance includes approximately **$20 million** in outflows for go-to-market realignment, with **$11 million** paid in Q1 and **$4 million** expected in Q2[11](index=11&type=chunk) - The company plans to repurchase approximately **$300 million** of common stock and retire **$500 million** in senior notes in FY2025[15](index=15&type=chunk) - Q2 FY2025 guidance includes approximately **9.5% constant currency ARR growth** and **$75 million** in share buybacks[9](index=9&type=chunk) [Key Metrics and Non-GAAP Measures](index=4&type=section&id=Key%20Metrics%20and%20Non-GAAP%20Measures) PTC utilizes key operating metrics like ARR and non-GAAP financial measures to evaluate performance and facilitate period-to-period comparisons - **ARR** is a key operating measure representing the annualized value of active subscription software, SaaS, hosting, and support contracts[20](index=20&type=chunk) - **Free Cash Flow** is defined as cash provided by operations net of capital expenditures, assessing the ability to generate cash without external financing[18](index=18&type=chunk) - **Constant Currency (CC)** information excludes foreign currency exchange rate fluctuations to assess underlying business performance, using rates as of September 30, 2024[19](index=19&type=chunk) - **Non-GAAP financial measures** exclude items such as stock-based compensation and amortization of acquired intangible assets to facilitate period-to-period comparisons of operating performance[17](index=17&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) Q1 FY2025 unaudited financial statements reveal a 3% revenue increase, significant net income growth, reduced cash and debt, and a 27% increase in operating cash flow [Consolidated Statements of Income](index=7&type=section&id=Consolidated%20Statements%20of%20Income) Q1 FY2025 Consolidated Statements of Income show a 2.7% increase in total revenue and a 23.9% increase in net income year-over-year Q1 FY2025 Income Statement Highlights (in thousands) | Line Item | Q1 2025 (Dec 31, 2024) | Q1 2024 (Dec 31, 2023) | YoY Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | $565,128 | $550,214 | +2.7% | | Recurring Revenue | $524,311 | $506,027 | +3.6% | | Gross Margin | $453,331 | $440,194 | +3.0% | | Operating Income | $115,524 | $118,713 | -2.7% | | **Net Income** | $82,232 | $66,387 | +23.9% | | **Diluted EPS** | $0.68 | $0.55 | +23.6% | [Condensed Consolidated Balance Sheets](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The Condensed Consolidated Balance Sheets indicate decreased cash and total assets, reduced net debt, and increased stockholders' equity Balance Sheet Highlights (in thousands) | Account | Dec 31, 2024 | Sep 30, 2024 | Change | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $196,338 | $265,808 | -$69,470 | | Total assets | $6,075,364 | $6,383,542 | -$308,178 | | Debt, net | $1,543,991 | $1,748,572 | -$204,581 | | Stockholders' equity | $3,229,821 | $3,214,398 | +$15,423 | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The Condensed Consolidated Statements of Cash Flows show a 27.3% increase in operating cash flow, with significant outflows for debt repayment and stock repurchases Q1 FY2025 Cash Flow Highlights (in thousands) | Line Item | Q1 2025 (Dec 31, 2024) | Q1 2024 (Dec 31, 2023) | YoY Change | | :--- | :--- | :--- | :--- | | **Net cash provided by operating activities** | $238,429 | $187,341 | +27.3% | | Capital expenditures | ($2,767) | ($4,563) | -39.4% | | **Free cash flow** | $235,662 | $182,778 | +28.9% | | Borrowings (payments) on debt, net | ($205,125) | $558,404 | N/A | | Repurchases of common stock | ($75,000) | $0 | N/A | [Reconciliation of GAAP to Non-GAAP Measures](index=9&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) This section reconciles GAAP to Non-GAAP financial measures, primarily adjusting for stock-based compensation and amortization of acquired intangible assets Q1 FY2025 GAAP to Non-GAAP Reconciliation (in thousands) | Metric | GAAP | Adjustments | Non-GAAP | | :--- | :--- | :--- | :--- | | **Operating Income** | $115,524 | +$75,806 | $191,330 | | **Operating Margin** | 20.4% | +13.5% | 33.9% | | **Net Income** | $82,232 | +$51,115 | $133,347 | | **Diluted EPS** | $0.68 | +$0.42 | $1.10 | - Primary adjustments for Non-GAAP operating income include **$55.9 million** in stock-based compensation and **$19.7 million** in amortization of acquired intangible assets[34](index=34&type=chunk)

Solid ARR and Cash FlowBOSTON, Feb. 5, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its first fiscal quarter ended December 31, 2024."In Q1'25, we delivered solid year-over-year constant currency ARR growth of 11% and cash flow growth above 25%, which was in-line with our guidance. Our differentiated strategy leverages our unique portfolio to help product companies accelerate their time to market and manage increasing complexity. It's an exciting time because our products are ...

Group 1 - Analysts expect PTC Inc. to report quarterly earnings of $0.91 per share, reflecting an 18% year-over-year decline [1] - Revenue is anticipated to be $551.92 million, which represents a 0.3% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [1][2] Group 2 - Analysts project 'Revenue- Recurring Revenue' to be $515.94 million, indicating a 2% year-over-year increase [4] - 'Revenue- Professional Services' is expected to reach $31.14 million, showing a decline of 12.9% from the previous year [4] - Total Software revenue (License + Support & Cloud Services) is forecasted at $522.72 million, reflecting a 1.6% year-over-year growth [4] Group 3 - 'Revenue- Perpetual License' is estimated at $6.76 million, indicating a 20% decrease from the prior-year quarter [5] - The average prediction for 'ARR as reported' stands at $2.28 billion, up from $2.06 billion reported in the same quarter last year [5] - PTC Inc. shares have increased by 2.7% over the past month, outperforming the Zacks S&P 500 composite's 1% increase [5]

PTC Inc (PTC) is scheduled to report first-quarter fiscal 2025 results on Feb. 5.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.For the quarter, PTC anticipates revenues between $540 million and $570 million. Non-GAAP EPS is expected in the range of 75 cents to 95 cents.The Zacks Consensus Estimate for revenues is pegged at $551.9 million, indicating an increase of 0.3% from the year-ago reported number. The consensus estimate for earnings is pegged at 91 cents per share, down 18% ...

BOSTON, Jan. 15, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 first quarter results on Wednesday, February 5th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, February 5th at 5 pm Eastern Time. The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the Company's website at P ...

Core Insights - PTC Therapeutics reported unaudited total revenue of approximately $814 million for 2024, exceeding guidance [1][5][11] - The company submitted four regulatory approval applications to the FDA in 2024, with significant upcoming decisions expected in 2025 [1][5][11] - PTC is preparing for the global launch of sepiapterin for PKU, targeting a market opportunity of $1 billion, with regulatory opinions expected in 2025 [1][5] - A collaboration agreement with Novartis for the PTC518 program has been finalized, providing substantial upfront proceeds and potential milestone payments [1][5][11] Financial Performance - The unaudited net product revenue for 2024 was approximately $601 million, with strong contributions from the DMD franchise, including $340 million from Translarna and $207 million from Emflaza [5][11] - The cash balance as of December 31, 2024, was approximately $1.1 billion, bolstered by $1.0 billion from the Novartis collaboration [5][11] - PTC anticipates total revenues for 2025 to range between $600 million and $800 million, including in-line products and potential new launches [12] Regulatory and Clinical Developments - PTC's regulatory submissions include Kebilidi, which was approved in November 2024, and sepiapterin, with an FDA action date set for July 29, 2025 [5][11] - The company expects results from the PIVOT-HD Phase 2 study of PTC518 in Q2 2025, with NDA acceptance for vatiquinone anticipated in Q1 2025 [11] - The CHMP opinion on sepiapterin's MAA is expected in Q2 2025, indicating ongoing regulatory engagement [5][11] Strategic Collaborations - The collaboration with Novartis includes a $1.0 billion upfront payment, potential for up to $1.9 billion in milestones, and a 40% profit share on U.S. sales [5][11] - Novartis will take over global development and commercialization responsibilities for PTC518 following the completion of the placebo-controlled portion of the PIVOT-HD study [5][11]

He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to init ...

WARREN, N.J., Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST.The presentation will be webcast live on the Events and Presentations page under the Investors section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recomme ...

Industry Overview - The fourth industrial revolution is characterized by the integration of smart digital technologies that work together iteratively in real time, greatly benefiting the manufacturing industry [16] - The first industrial revolution was driven by steam power and mechanical production, the second by electricity and mass production, and the third by the information age (semiconductors, computing, and the internet) [2] - Spending on digital transformation is expected to grow at a 16.2% compound annual growth rate from 2022 to 2027, reaching $3.9 trillion compared to $1.9 trillion in 2022 [5] PTC's Role in the Industry - PTC's software plays a pivotal role in the fourth industrial revolution, particularly through its closed-loop digital thread, which gathers data across a product's entire life cycle to improve processes iteratively [3][16] - The company's software suite includes computer-aided design (CAD), product life-cycle management (PLM), Internet of Things (IoT), augmented reality (AR), and software life cycle management (SLM) solutions [10][17] - PTC's software enables manufacturers to shorten development timelines while maintaining high quality, integrating hardware, mechanical, electronic, and embedded software processes [18] PTC's Growth Strategy - PTC is refocusing on its five key industry verticals: industrial products, aerospace and defense, electronics and technology, automaking, and medical technology and life sciences to drive ARR growth [19] - The company recently appointed Robert Dahdah, former Microsoft vice president, as chief revenue officer to lead sales and customer success for its Digital Thread group and new market strategy [13] - PTC's annual run rate (ARR), which includes subscription software, SaaS, and support contracts, continues to show double-digit growth despite economic challenges [18] Market Potential - The increasing adoption of digital technologies is expected to amplify the value PTC provides to its manufacturing customers, leading to significant growth for the company in the medium and long term [15] - Industry forecasters expect PTC to grow at a mid-teens rate over the next decade, driven by the ongoing investment in digital technology and the fourth industrial revolution [20] - Lower interest rates and a potential pick-up in industrial spending are seen as additional benefits for PTC's growth prospects [14]